Hoffmann, Donata http://orcid.org/0000-0003-4552-031X
Corleis, Björn
Rauch, Susanne
Roth, Nicole
Mühe, Janine
Halwe, Nico Joel http://orcid.org/0000-0002-7983-2808
Ulrich, Lorenz http://orcid.org/0000-0001-5004-806X
Fricke, Charlie http://orcid.org/0000-0001-7493-6627
Schön, Jacob
Kraft, Anna http://orcid.org/0000-0002-9081-183X
Breithaupt, Angele http://orcid.org/0000-0002-6373-5923
Wernike, Kerstin http://orcid.org/0000-0001-8071-0827
Michelitsch, Anna http://orcid.org/0000-0002-5981-9905
Sick, Franziska
Wylezich, Claudia http://orcid.org/0000-0002-0436-4480
Hoffmann, Bernd
Thran, Moritz
Thess, Andreas http://orcid.org/0000-0001-8432-8959
Mueller, Stefan O.
Mettenleiter, Thomas C.
Petsch, Benjamin
Dorhoi, Anca http://orcid.org/0000-0003-1739-749X
Beer, Martin http://orcid.org/0000-0002-0598-5254
Funding for this research was provided by:
Bundesministerium für Bildung und Forschung (01KI20703)
CureVac, Tübingen, Germany. Bundesministerium für Ernährung und Landwirtschaft (Federal Ministry of Food and Agriculture) Core funding
Article History
Received: 2 April 2021
Accepted: 14 June 2021
First Online: 30 June 2021
Competing interests
: S.R., B.P., N.R., J.M., A.T., M.T., and S.O.M. are employees of CureVac AG, Tübingen, Germany, a publically listed company developing mRNA-based vaccines and immunotherapeutics. Authors may hold shares in the company. S.R., B.P., N.R., A.T., and M.T. are inventors on several patents on mRNA vaccination and use thereof.